How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,447 results for

Esophageal Dysphagia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: Yes Keywords provided by Andrew C Hecht, Icahn School of Medicine at Mount Sinai: Esomeprazole Magnesium Postoperative dysphagia Gastroesophageal reflux disease Anterior cervical surgery Proton pump inhibitor Additional relevant MeSH terms: Layout table for MeSH terms Deglutition Disorders Joint Diseases Osteoarthritis Esophageal Diseases (...) at Mount Sinai Study Details Study Description Go to Brief Summary: The researchers wish to investigate whether proton pump inhibitors, administered prior to or after surgery, can reduce the incidence and/or severity of difficulty swallowing foods and/or liquids,following anterior cervical surgery. Condition or disease Intervention/treatment Phase Dysphagia GERD Degenerative Joint Disease Drug: Esomeprazole Drug: Placebo Oral Tablet Phase 2 Detailed Description: Over half of patients who underwent

2018 Clinical Trials

2. Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: Yes Keywords provided by Ajay Wasan, MD, Msc, University of Pittsburgh: Abuse-deterrent opioid drugs Xtampza ER Additional relevant MeSH terms: Layout table for MeSH terms Chronic Pain Deglutition Disorders Pain Neurologic Manifestations Signs and Symptoms Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Pharyngeal Diseases (...) Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Use of Xtampza ER

2018 Clinical Trials

3. Swallowing difficulties with medication intake assessed with a novel self-report questionnaire in patients with systemic sclerosis – a cross-sectional population study Full Text available with Trip Pro

Swallowing difficulties with medication intake assessed with a novel self-report questionnaire in patients with systemic sclerosis – a cross-sectional population study To assess subjective swallowing difficulties (SD) with medication intake and their practical consequences in patients suffering from systemic sclerosis (SSc) with a novel self-report questionnaire.Based on a systematic literature review, we developed a self-report questionnaire and got it approved by an expert panel (...) , and Adherence. Of the 64 SSc patients eligible in 2014, 43 (67%) returned the questionnaire. Twenty patients reported SD with medication intake (prevalence 47%), either currently (11; 26%) or in the past that had been overcome (9; 21%). Self-reported SD were localized mostly in the larynx (43%) and esophagus (34%). They were of moderate (45%) or strong to unbearable intensity (25%). Modification of the dosage form was reported in 40% of cases with SD. Adherence was poor for 20 (47%) patients

2017 Patient preference and adherence

4. Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. Full Text available with Trip Pro

Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. Adequate upper oesophageal sphincter (UOS) opening is critical to safe and efficient swallowing due to the close proximity of the UOS to the airway entrance. Many people with neurological conditions, progressive and non-progressive, present with UOS dysfunction. The consequences for the person include difficulty swallowing food with subsequent choking and aspiration (passage of material (...) ); Clinical Trials (http://www.clinicaltrials.gov); Chinese Clinical Trial Register (www.chictr.org); ACTR (http://www.actr.org.au/. We examined the reference lists of all potentially relevant studies to identify further relevant trials. We handsearched published abstracts of conference proceedings from both the Dysphagia Research Society and the European Society of Swallowing Disorders. Digestive Disease Week (published in Gastroenterology) was also handsearched. Additionally, we searched ProQuest

2014 Cochrane

5. Esophageal Dysphagia

. Oropharyngeal dysphagia is described as dif- ficulty initiating a swallow or passing food through the region of the mouth or throat; whereas, esophageal dysphagia refers to difficulty in transferring material down the esophagus in the retrosternal region (2). Patients with certain diseases or disorders are at increased risk of oropharyngeal dysphagia and a diagnosis of these conditions should direct attention to the possibility of its presence. Some conditions such as stroke; head and neck cancer; surgery (...) Strategy: -------------------------------------------------------------------------------- 1 exp Deglutition Disorders/ (74138) 2 exp Deglutition/ (18795) 3 dysphagia.mp. (55554) 4 exp dysphagia/ (74138) 5 exp swallowing/ (18795) 6 swallow*.mp. (46835) 7 1 or 2 or 3 or 4 or 5 or 6 (122463) 8 (esophag* or oesophag*).mp. (346880) 9 oropharyn*.mp. (36252) 10 8 and 9 (3428) 11 7 and 10 (1178) 12 (oral-pharyn* or oropharyn*).mp. (37124) 13 (eso-phag* or oeso-phag* or esophag* or oesophag*).mp. (346882) 14

2018 Canadian Association of Gastroenterology

6. Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial. Full Text available with Trip Pro

neoadjuvant chemoradiotherapy (nCRT) and further to study the association between dysphagia response and histological response. Patient reported swallowing function was a secondary endpoint in the NeoRes trial, in which patients were randomized between neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. Patients completed dysphagia questionnaires before the start and after neoadjuvant therapy, using the European Organization for Research and Treatment of Cancer (EORTC) esophageal cancer modules QLQ (...) Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial. Dysphagia is the most significant symptom in patients with esophageal cancer. There are different therapeutic interventions designed to relieve dysphagia, but few studies have addressed the effects of neoadjuvant therapy. The aim of this study is to compare the effects on dysphagia of neoadjuvant chemotherapy (nCT) versus

2019 Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus Controlled trial quality: uncertain

7. European Society for Swallowing Disorders FEES Accreditation Program for Neurogenic and Geriatric Oropharyngeal Dysphagia Full Text available with Trip Pro

of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, Great Britain. Clave P P Centro de Investigación Biomédica en Red de Enfermedades, Hepáticas y Digestivas (CIBERehd), Hospital de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain. European Society for Swallowing Disorders eng Editorial 2017 08 04 United States Dysphagia 8610856 0179-051X IM Accreditation Curriculum Deglutition Deglutition (...) European Society for Swallowing Disorders FEES Accreditation Program for Neurogenic and Geriatric Oropharyngeal Dysphagia 28779300 2018 11 01 2018 11 13 1432-0460 32 6 2017 Dec Dysphagia Dysphagia European Society for Swallowing Disorders FEES Accreditation Program for Neurogenic and Geriatric Oropharyngeal Dysphagia. 725-733 10.1007/s00455-017-9828-9 Dziewas R R Department of Neurology, University Hospital Münster, Münster, Germany. dziewas@uni-muenster.de. Baijens L L Department

2017 Dysphagia

8. Performance status is a predictive factor of dysphagia improvement after esophageal stenting in patients with malignant esophageal strictures and fistulas. (Abstract)

Performance status is a predictive factor of dysphagia improvement after esophageal stenting in patients with malignant esophageal strictures and fistulas. Malignant strictures and fistulas of the esophagus adversely affect quality of life (QOL) and prognosis, and stenting is considered a useful therapy for improving QOL. However, the predictive factors for improving dysphagia after esophageal stenting are unclear. This retrospective cohort study aimed to evaluate patients with esophageal (...) malignant strictures and fistulas who underwent stenting and investigate the factors for dysphagia improvement after stenting.Twenty-four patients with malignant esophageal strictures and fistulas were treated with a self-expandable metallic stent over a period of 5 years and 6 months. The main outcome was improvement in the dysphagia score. We divided the patients into dysphagia improved and non-improved groups after esophageal stenting. Sex, age, cause of stenting (primary or non-primary esophageal

2019 Surgical endoscopy

9. Sucking and swallowing difficulties in infancy: diagnostic problem of dysphagia. Full Text available with Trip Pro

Sucking and swallowing difficulties in infancy: diagnostic problem of dysphagia. 4901820 1970 01 24 2018 11 13 1468-2044 44 238 1969 Dec Archives of disease in childhood Arch. Dis. Child. Sucking and swallowing difficulties in infancy: diagnostic problem of dysphagia. 655-65 Illingworth R S RS eng Journal Article Review England Arch Dis Child 0372434 0003-9888 IM Adolescent Adult Child Child, Preschool Congenital Abnormalities complications Deglutition Disorders classification diagnosis (...) etiology Esophagitis complications Female Humans Infant Infant, Newborn Infant, Newborn, Diseases Male Paralysis complications Prognosis Stomatitis complications 79 1969 12 1 1969 12 1 0 1 1969 12 1 0 0 ppublish 4901820 PMC2020353 Med Biol Illus. 1967 Jul;17(3):191-7 6041477 Pediatrie. 1955;10(1):37-59 14384382 AMA Am J Dis Child. 1954 Feb;87(2):179-91 13123534 Pediatrics. 1965 Jan;35:3-19 14223223 Am J Dis Child. 1965 Nov;110(5):556-8 5846694 Arch Dis Child. 1967 Jun;42(223):308-10 6025372

1969 Archives of Disease in Childhood

10. Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis

focusing on COping strategies (SWAMECO). Condition or disease Systemic Sclerosis Deglutition Disorders Adherence to Medication Regime Coping Behaviour Scleroderma, Systemic Detailed Description: The study aims at investigating a cohort of patients with diagnosed systemic sclerosis using the newly developed self-report SWAMECO-questionnaire. The self-report questionnaire is sub-divided into four sections: detection of swallowing difficulties, coping strategies, risk factors to develop swallowing (...) difficulties and adherence to medication. This study involves patients with systemic sclerosis. Systemic sclerosis often is accompanied by swallowing disorders which may lead to issues in handling medication regimen with risks for patient safety. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 64 participants Observational Model: Cohort Time Perspective: Cross-Sectional Official Title: Swallowing Difficulties With Medication Intake and Coping Strategies

2014 Clinical Trials

11. Effect of Bolus Viscosity on the Safety and Efficacy of Swallowing and the Kinematics of the Swallow Response in Patients with Oropharyngeal Dysphagia: White Paper by the European Society for Swallowing Disorders (ESSD) Full Text available with Trip Pro

Effect of Bolus Viscosity on the Safety and Efficacy of Swallowing and the Kinematics of the Swallow Response in Patients with Oropharyngeal Dysphagia: White Paper by the European Society for Swallowing Disorders (ESSD) Fluid thickening is a well-established management strategy for oropharyngeal dysphagia (OD). However, the effects of thickening agents on the physiology of impaired swallow responses are not fully understood, and there is no agreement on the degree of bolus thickening.To review (...) with oropharyngeal dysphagia; bolus modification; effects of bolus modification on swallow safety (penetration/aspiration) and efficacy; and/or physiology and original articles written in English. The exclusion criteria consisted of oesophageal dysphagia and conference abstracts or presentations. The quality of the selected papers and the level of research evidence were assessed by standard quality assessments.At the end of the selection process, 33 articles were considered. The quality of all included studies

2016 Dysphagia

12. IQoro for stroke-related dysphagia

IQoro for stroke-related dysphagia IQoro for strok IQoro for stroke-related dysphagia e-related dysphagia Medtech innovation briefing Published: 6 March 2019 www.nice.org.uk/guidance/mib175 pathways Summary Summary The technology technology described in this briefing is IQoro. It is a neuromuscular training device used for stimulating the nerves and strengthening the muscles in the face, mouth, throat, oesophagus, and diaphragm. Swallowing therapy is the usual treatment for dysphagia (...) (difficulty starting to swallow) after a stroke. The inno innovativ vative aspect e aspect is that the company claims swallowing exercises can be more accurately and effectively done using IQoro. No similar technologies are currently recommended in care guidelines. The intended place in ther place in therap apy y would be as well as standard speech and language therapy in people with stroke-related dysphagia. The main points from the e main points from the evidence vidence summarised in this briefing

2019 National Institute for Health and Clinical Excellence - Advice

13. Treatment for upper esophageal sphincter dysfunction in a patient with poststroke dysphagia: A case report. Full Text available with Trip Pro

Treatment for upper esophageal sphincter dysfunction in a patient with poststroke dysphagia: A case report. Botulinum toxin injection is a widely used procedure for the treatment of the dysfunction of the upper esophageal sphincter (UES). Although the injection can be guided by ultrasound, electromyography, or computed tomography, such techniques cannot determine the exact extent of narrowed UES and ensure that the narrowed extent is fully covered by the treatment. This report describes a dual (...) guiding technique with ultrasound and the balloon catheter in a patient with poststroke dysphagia to improve these weaknesses.The patient was admitted to a rehabilitation hospital 2 weeks postcerebral infarction.Clinical presentation of the patient included severe hemiplegia and dysphagia. The fiberoptic endoscopic evaluation of swallowing (FEES) revealed penetration/aspiration when swallowing 1 ml water and 1 ml yogurt and pooling in the postcricoid region.Balloon catheter dilatation procedures

2019 Medicine

14. Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. (Abstract)

Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC.This retrospective study included 434 consecutive patients with EC who received docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy (...) as an initial treatment. We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival.The dysphagia scores were 0 in 208 patients (47.9%), 1 in 82 patients (18.9%), 2 in 52 patients (12.0%), 3 in 59 patients (13.6%), and 4 in 33 patients (7.6%). High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79.3 vs. 35.7%, P < 0.001

2019 Annals of Surgical Oncology

15. Effect of citalopram on esophageal motility in healthy subjects-Implications for reflux episodes, dysphagia, and globus. (Abstract)

Effect of citalopram on esophageal motility in healthy subjects-Implications for reflux episodes, dysphagia, and globus. Drugs such as citalopram, "targeting" the serotonin pathway, can alter esophageal mechano-chemical sensitivity and gastrointestinal motility. The aim of this study was to clarify the effect of citalopram on esophageal motility and sphincter function, transient lower esophageal sphincter relaxations (TLESRs), and reflux events.Sixteen healthy volunteers (HV) receiving 20 mg (...) citalopram or placebo intravenously, in a randomized cross-over fashion, underwent two high-resolution impedance manometry studies involving liquid swallows and a high-fat, high-caloric meal. Manometric, reflux, and symptom-related parameters were studied.A lower distal contractile integral was recorded under citalopram, compared with placebo (P = 0.026). Upper esophageal sphincter (UES) resting pressure was significantly higher after citalopram administration throughout the study (P < 0.05, all periods

2019 Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society Controlled trial quality: uncertain

16. Esophageal IgE, IgG4, and mucosal eosinophilia in individuals with dysphagia. (Abstract)

Esophageal IgE, IgG4, and mucosal eosinophilia in individuals with dysphagia. Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, producing failure to thrive in infants and dysphagia with food impaction in older children and adults. Although most people with EoE manifest atopic/allergic disease, the specific allergens to which immunoglobulin E (IgE) is directed, if any, have not yet been characterized.Mucosal brush biopsy (MBB) and solid tissue biopsy (STB) specimens (...) . Clarifying the role of both IgE-mediated and non-IgE-mediated inflammatory mechanisms will help identify more targeted diagnostic and treatment strategies for individuals who present with dysphagia and esophageal eosinophilia.© 2019 ARS-AAOA, LLC.

2019 International forum of allergy & rhinology

17. A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. (Abstract)

A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. Studies suggest that Ineffective Esophageal Motility (IEM) is the manometric correlate of Functional Dysphagia (FD). Currently, there is no accepted therapy for either condition. Buspirone is a serotonin modulating medication and has been shown to augment esophageal peristaltic amplitude in healthy volunteers. We aimed to determine if buspirone improves (...) manometric parameters and symptoms in patients with overlapping IEM/FD.We performed a prospective, double-blind, placebo-controlled, crossover-style trial of 10 patients with IEM/FD. The study consisted of two 2-week treatment arms with a 2-week washout period. Outcomes measured at baseline, end of week 2, and week 6 include high resolution esophageal manometry (HREM), the Mayo Dysphagia Questionnaire-14 (MDQ-14), and the GERD-HRQL.The mean age of our 10 patients was 53 ± 9 years and 70% were female

2018 Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society Controlled trial quality: uncertain

18. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). (Abstract)

Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. We compared chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.This multicentre randomised controlled trial included patients with advanced or metastatic (...) oesophageal cancer who were randomly assigned (1:1) through a computer-generated adaptive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zealand, and the UK. Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological and renal function. Patients

2018 The lancet. Gastroenterology & hepatology Controlled trial quality: predicted high

19. Addendum to A study of dysphagia symptoms and esophageal body function in children undergoing anti-reflux surgery Full Text available with Trip Pro

Addendum to A study of dysphagia symptoms and esophageal body function in children undergoing anti-reflux surgery 30288290 2018 11 14 2050-6406 6 8 2018 Oct United European gastroenterology journal United European Gastroenterol J Addendum to A study of dysphagia symptoms and esophageal body function in children undergoing anti-reflux surgery . 1274-1275 10.1177/2050640618798487 Omari Taher T https://orcid.org/0000-0001-5108-7378 Department of Human Physiology, College of Medicine and Public

2018 United European gastroenterology journal

20. Assessment of Esophageal High-Resolution Impedance Manometry in Patients with Nonobstructive Dysphagia Full Text available with Trip Pro

than that in the non-GERD patients (8.1 ± 1.1 sec versus 5.5 ± 0.3 sec, P < 0.05). And in the seven patients with normal esophagus function, 3.5% swallows showed ICET and BTT was 5.6 ± 0.3 sec.Achalasia was the most common esophageal dysmotility in NOD patients, followed by nonspecific esophageal motility disorders. The clinical diagnoses of NOD were mostly achalasia and GERD. Impedance assessments showed that all achalasia cases exhibited ICET, and other esophageal motility abnormalities (...) patients with esophagogastric junction outflow obstruction showed ICET, and the average bolus transit time (BTT) was 6.6 ± 1.2 sec. In 20 nonspecific esophageal motility disorders, 13 patients with gastroenterologly reflux disease (GERD) presented ineffective esophageal motility and fragmented peristalsis, and 65.0% swallows had exhibited ICET. However, 49.1% swallows of 7 nonspecific esophageal motility disorder patients with non-GERD had exhibited ICET. The average BTT in 13 GERD patients was longer

2018 Gastroenterology research and practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>